Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.
about
In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strainsInteractions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticusIncreasing resistance to vancomycin and other glycopeptides in Staphylococcus aureusSynergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelActivities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelGlycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity.Efficacy of novel antibacterial compounds targeting histidine kinase YycG protein.Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) functionVancomycin resistance in staphylococci.Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against itDaptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Mutations in the primary sigma factor σA and termination factor rho that reduce susceptibility to cell wall antibiotics.Biological properties of novel antistaphylococcal quinoline-indole agents.Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitisInfluence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptidesIn vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides.Vancomycin microspheres reduce postoperative spine infection in an in vivo rabbit modelSpontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus.Synergy of β-Lactams with Vancomycin against Methicillin-Resistant Staphylococcus aureus: Correlation of Disk Diffusion and Checkerboard Methods.CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.Synergistic action of cinnamaldehyde with silver nanoparticles against spore-forming bacteria: a case for judicious use of silver nanoparticles for antibacterial applications.Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycinMechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics.Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureusFailure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.
P2860
Q21093290-963E1EC5-A26F-4182-9FD5-CDD1E7A2A684Q24549505-D9AF5A7F-2ACE-45F9-9D82-D48FEDA32C45Q28362193-1EFB3E64-754B-42F2-BE25-CC99C4F42E56Q28481497-EEAFEF22-C099-4430-9AB7-3BD63DBE2BA4Q33593883-73DA58E9-0CEE-49FE-889A-ECC8A7CEF010Q33594576-81AE36B4-5DD8-4A99-BEEB-AB53889158C2Q33700986-07134DC5-54D1-47EB-AD32-5B75E4EBC1C6Q33755387-CC6A7E58-309F-4562-A6AF-0E09FF7E7018Q33883752-6DC6285D-3B95-4FF3-B6F0-359B9C670B95Q33906522-210964C1-A2E9-4E10-A975-E71768734CF9Q33951678-5F997CEB-234C-478E-A6F9-251754D05E2AQ34045273-5E1A03CA-F245-410B-8091-2C156399608AQ34110412-92EB7C37-BA10-42B2-89AC-F350D3F1523FQ34593241-5EA09AEA-065B-4397-93D5-1E9A0E3FE0E6Q34821242-5A51FE9C-08E6-4D3C-80DF-ED21A5254013Q35013994-8C04580F-FA19-41BF-B705-5DF1F52FCC14Q35014464-0562C3D6-51BC-409F-8C4D-78F1D60ADEEFQ35083990-895D0047-0FF2-4E7F-9124-375B04BEDC84Q35191417-967E3BBF-982C-4FB0-B9E5-4471B62F01C9Q35665343-A7F13450-0997-4958-90D7-C82E1968D862Q36207193-558C6576-4FD0-4FCC-B3B4-07E6A22858E6Q36538634-305266AB-83D4-41AF-94B1-02873D7AB12CQ36620815-5F24CAA4-DA53-4D69-8C6D-2F99029CB97CQ36748977-1A6F6CC9-7118-4CAC-9C4F-C1D0A7308C62Q37203885-FD0326E2-1B68-4BD6-80FA-20B764B0ABBFQ37396688-5968A41D-D43F-442D-8E5A-46DF8B9964A5Q39476999-64993B81-D942-43BC-BE24-71D64073AA49Q39477127-CC645958-A201-48DE-99D9-80F4D76D4F15Q39537168-B3C0E256-F562-40C7-BEA6-2B10D3195FB8Q39651918-A8C25E89-2662-4386-A093-8532C125B69BQ39652231-E9946C15-3829-4709-AA71-53A37404CEFAQ40003834-7002CDF5-2FE3-475E-A815-2848E4266279Q40326741-F3C8DE8D-71FA-4AFB-8C30-5D471F69F470Q41092910-2D44B3CB-3403-4CE5-8257-ED72F137660FQ41814975-5113569B-9049-4849-9F01-5A9A5F288031Q42001450-331AF7B7-488C-45BF-A877-9ACEB936BED6Q42090736-E5C2ED3F-7743-4235-9428-A289CF752808Q42147280-206BF872-3419-47CF-B4E3-41E1C3E6ABBAQ42929761-D7567854-D65B-4B8F-A0F9-06FE69A50A82Q43378543-26C2D62D-FFF9-43B4-8F30-EA4819276DB6
P2860
Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@ast
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@en
type
label
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@ast
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@en
prefLabel
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@ast
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@en
P2093
P2860
P1476
Combinations of vancomycin and ...... usceptibilities to vancomycin.
@en
P2093
P2860
P304
P407
P577
1999-07-01T00:00:00Z